☆ 4.7 Article

Molecular subtypes predict therapeutic responses and identifying and validating diagnostic signatures based on machine learning in chronic myeloid leukemia

CANCER CELL INTERNATIONAL (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Tissue-Specific microRNA Expression Profiling to Derive Novel Biomarkers for the Diagnosis and Subtyping of Small B-Cell Lymphomas

Susan Swee-Shan Hue et al.

Summary: It is challenging for pathologists to accurately diagnose small B-cell lymphomas due to overlapping morphological features and limitations of current ancillary testing. In this study, we identified and validated two sets of microRNA biomarkers that can distinguish small B-cell lymphomas from reactive lymphoid tissue and differentiate between the subtypes of these lymphomas. This study suggests that miRNA expression profiling may serve as a promising diagnostic tool for small B-cell lymphomas.

CANCERS (2023)

添加到收藏夹

Article

Combined scRNAseq and Bulk RNAseq Analysis to Reveal the Dual Roles of Oxidative Stress-Related Genes in Acute Myeloid Leukemia

Jing Qi et al.

Oxidative Medicine and Cellular Longevity (2023)

添加到收藏夹

Article Oncology

Sphingomyelin Phodiesterase Acid-Like 3A Promotes Hepatocellular Carcinoma Growth Through the Enhancer of Rudimentary Homolog

Yu Zhang et al.

Summary: High expression of SMPDL3A in HCC was associated with poor prognosis. Knockout of SMPDL3A inhibited cell proliferation and migration in HCC cells. SMPDL3A interacted with ERH to affect the tumorigenesis and progression of HCC.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Hematology

Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring

Elias Jabbour et al.

Summary: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm characterized by a genetic translocation and fusion gene. Tyrosine kinase inhibitors (TKIs) are the frontline therapy, but second-line options are available for patients who develop resistance. Stem cell transplantation and non-TKI agents are recommended for advanced disease and relapse patients.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

添加到收藏夹

Review Oncology

Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia

Govinda Poudel et al.

Summary: This article reviews the lack of response or relapse of chronic myeloid leukemia (CML) patients to current drug treatments, as well as new treatment strategies. Combination treatment strategies targeting alternative survival pathways may increase the response rate in CML patients.

CANCERS (2022)

添加到收藏夹

Review Hematology

Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions

Afaf E. G. Osman et al.

Summary: CML is a myeloproliferative neoplasm caused by a specific gene fusion, with the majority of patients benefiting from BCR/ABL1 tyrosine kinase inhibitors, leading to long-term remission. However, a small percentage of patients develop resistance and may require hematopoietic stem cell transplantation for cure. Research focuses on overcoming TKI resistance, improving outcomes in BP-CML, and enhancing rates of TFR in CML.

BLOOD REVIEWS (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

AQP3 and AQP5-Potential Regulators of Redox Status in Breast Cancer

Lidija Milkovic et al.

Summary: Breast cancer remains a leading cause of female mortality, with aquaporins AQP3 and AQP5 playing significant roles in its development. Researchers are exploring the potential of targeting these aquaporins for new therapies in breast cancer treatment.

MOLECULES (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Relationship between Oxidative Stress and Imatinib Resistance in Model Chronic Myeloid Leukemia Cells

Sylwester Glowacki et al.

Summary: Chronic myeloid leukemia (CML) is caused by the BCR-ABL1 protein, inducing oxidative stress and leading to resistance to imatinib (IM). Research shows increased ROS accumulation in BCR-ABL1 positive cells, heightened DNA damage in IM-sensitive cells, and alterations in antioxidant enzyme activity and mitochondrial potential in IM-resistant cells.

BIOMOLECULES (2021)

添加到收藏夹

Article Genetics & Heredity

Large-scale public data reuse to model immunotherapy response and resistance

Jingxin Fu et al.

GENOME MEDICINE (2020)

添加到收藏夹

Article Medicine, Research & Experimental

MiR-877 suppresses gastric cancer progression by downregulating AQP3

Hongyu Zhu et al.

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2020)

添加到收藏夹

Review Oncology

RNA sequencing: new technologies and applications in cancer research

Mingye Hong et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

添加到收藏夹

Article Toxicology

Functional Profiling Identifies Determinants of Arsenic Trioxide Cellular Toxicity

Amin Sobh et al.

TOXICOLOGICAL SCIENCES (2019)

添加到收藏夹

Article Oncology

HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia

Jong-Ho Park et al.

LEUKEMIA (2019)

添加到收藏夹

Review Hematology

Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring

Elias Jabbour et al.

AMERICAN JOURNAL OF HEMATOLOGY (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

Peng Jiang et al.

NATURE MEDICINE (2018)

添加到收藏夹

Review Biochemistry & Molecular Biology

Reactive oxygen species in BCR-ABL1-expressing cells - relevance to chronic myeloid leukemia

Joanna Antoszewska-Smith et al.

ACTA BIOCHIMICA POLONICA (2017)

添加到收藏夹

Letter Oncology

Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?

V. Nemethova et al.

LEUKEMIA (2017)

添加到收藏夹

Article Medicine, General & Internal

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

Andreas Hochhaus et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Hematology

Dual mechanisms by which miR-125b represses IRF4 to induce myeloid and B-cell leukemias

Alex Yick-Lun So et al.

BLOOD (2014)

添加到收藏夹

Article Oncology

NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia

Beatriz Sanchez-Sanchez et al.

CLINICAL CANCER RESEARCH (2014)

添加到收藏夹

Article Multidisciplinary Sciences

Sensitive Detection of Pre-Existing BCR-ABL Kinase Domain Mutations in CD34+Cells of Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients Is Associated with Imatinib Resistance: Implications in the Post-Imatinib Era

Zafar Iqbal et al.

PLOS ONE (2013)

添加到收藏夹

Article Pharmacology & Pharmacy

Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells

Jelena Klawitter et al.

BRITISH JOURNAL OF PHARMACOLOGY (2009)

添加到收藏夹

Article Hematology

The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells

Karl J. Aichberger et al.

BLOOD (2006)

添加到收藏夹

Article Hematology

Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species

JH Kim et al.

BLOOD (2005)

添加到收藏夹

Article Biochemistry & Molecular Biology

Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region

CA Ortmann et al.

NUCLEIC ACIDS RESEARCH (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.